Gubra AS (HAM:PI3) reports competitive weight loss data for its amylin analog, initiates Phase 2 for its triple agonist, and establishes Gubra Ventures to drive external innovation.

As European markets experience a notable upswing, with the STOXX Europe 600 Index climbing over 3% amid improved geopolitical conditions, investors are keenly observing the small-cap segment for opportunities. In this environment of cautious optimism, identifying stocks that demonstrate strong fundamentals and potential insider confidence can be crucial in navigating the evolving market landscape.

Gubra AS (STU:PI3) reports a robust financial performance with strategic expansions and investments, despite facing challenges in the US biotech market.

As the pan-European STOXX Europe 600 Index sees a modest rise, buoyed by resilient economic data and earnings results, investors are increasingly exploring opportunities beyond the well-trodden paths of large-cap stocks. In this environment, identifying promising small-cap companies with strong fundamentals and growth potential can be crucial to enhancing a diversified portfolio.

Amylyx Pharmaceuticals recently selected AMX0318, a long-acting GLP-1 receptor antagonist discovered in collaboration with Gubra, as a development candidate for post-bariatric hypoglycemia and other rare diseases, following extensive preclinical evaluation and with IND-enabling studies planned ahead of a potential 2027 filing. Under this collaboration, Gubra receives an immediate US$4,000,000 milestone for the candidate handover and could earn more than US$50,000,000 in additional milestones...

Why Gubra Stock Is On Investors’ Radar Today Gubra (CPSE:GUBRA) is back in focus after recent trading, with the share price closing at DKK 444.6. Investors are weighing the latest return figures against the company’s current earnings profile. See our latest analysis for Gubra. The recent 0.41% 1 day share price return sits against a 7 day share price return of 9.89% and a 30 day share price return of 12.99%. The 1 year total shareholder return of 18.85% and year to date share price return of...

AbbVie Inc. (NYSE:ABBV) is one of the 10 Goldman Sachs undervalued stocks to invest in. On January 14, 2026, Reuters reported that AbbVie Inc. (NYSE:ABBV) is looking to deepen its push into the rapidly growing obesity-treatment market, outlining its plans at the JPMorgan Healthcare Conference. The company’s plans center on GUBamy, an amylin-mimetic weight-loss drug […]

Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the overlooked growth stocks to buy. On January 8, Amylyx Pharmaceuticals (NASDAQ:AMLX) announced the nomination of AMX0318 as its newest development candidate. Identified through a strategic collaboration with Gubra A/S, AMX0318 is a novel, long-acting glucagon-like peptide-1/GLP-1 receptor antagonist designed to treat post-bariatric hypoglycemia/PBH and other rare diseases. […]

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is one of the best performing pharma stocks in 2025. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) announced on January 8 the selection of AMX0318 as a development candidate for post-bariatric hypoglycemia (PBH) and other rare diseases. AMX0318 is a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist and was identified through a research collaboration with […]